EditorialGLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes
Section snippets
Conflict of interest
The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.
References (20)
- et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Lancet
(2004) - et al.
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
Cardiovasc. Diabetol.
(2017) - et al.
Inhibition of plaque progression and promotion of plaque stability by glucagon-like Peptide-1 receptor agonist: serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits
Atheroslcerosis
(2017) - et al.
Clinical characterization of coronary atherosclerosis with dual-modality OCT and near-infrared autofluorescence imaging
JACC Cardiovasc Imaging
(2016) - et al.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
Lancet
(2010) - et al.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
N. Engl. J. Med.
(1998) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Lancet
(2002)Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
J. Am. Med. Assoc.
(2002)- et al.
Current perspectives on cardiovascular outcome trials in diabetes
Cardiovasc. Diabetol.
(2016) - et al.
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Cardiovasc. Diabetol.
(2014)
There are more references available in the full text version of this article.
Cited by (1)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE <sup>−/−</sup> and LDLr <sup>−/−</sup> Mice by a Mechanism That Includes Inflammatory Pathways
2018, JACC: Basic to Translational ScienceCitation Excerpt :Lixisenatide, another short-acting GLP-1RA, did not provide evidence of CV RR in the ELIXA (The Evaluation of Lixisenatide in Acute Coronary Syndrome) trial (4). Differences in patient populations and trial duration could explain the differences in outcome, but the duration of action by these different GLP-1RAs might also be relevant for the CV RR (48). It is well documented that the actions of GLP-1RAs have a strict pharmacokinetic-to-pharmacodynamic relationship (49).
Crown Copyright © 2017 Published by Elsevier Ireland Ltd. All rights reserved.